Mabpharm Dividende

Dividende contrôle des critères 0/6

Mabpharm does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Rendement des rachats

Rendement total pour l'actionnaire	n/a
Rendement futur des dividendes	n/a
Croissance des dividendes	n/a
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Ratio de distribution	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if 2181's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if 2181's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Mabpharm Rendement des dividendes par rapport au marché

Comment le rendement du dividende de 2181 se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (2181)	n/a
25% du marché (HK)	3.2%
25% du marché (HK)	7.9%
Moyenne du secteur (Biotechs)	1.1%
Analyste prévisionnel (2181) (jusqu'à 3 ans)	n/a

Dividende notable: Unable to evaluate 2181's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate 2181's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate 2181's payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as 2181 has not reported any payouts.

Mabpharm Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.024 loss in 1H 2023)

Mabpharm Limited to Report First Half, 2024 Results on Aug 28, 2024

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Approval from the Ministry of Health of Peru on the New Drug Application of CMAB008 (Infliximab for Injection)

Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Mabpharm Limited, Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.051 loss in FY 2022)

Mabpharm Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm Limited Announces Director Changes

First half 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.028 loss in 1H 2022)

Mabpharm Limited to Report First Half, 2023 Results on Aug 25, 2023

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.071 loss in FY 2021)

Less than half of directors are independent

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Mabpharm Limited to Report First Half, 2022 Results on Aug 26, 2022

Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis

Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017

Less than half of directors are independent

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

First half 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.013 loss in 1H 2020)

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$1.18

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

New 90-day low: HK$1.08

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

New 90-day low: HK$1.14

Mabpharm Limited Announces CEO Changes

New 90-day low: HK$1.15

Mabpharm Limited to Report First Half, 2020 Results on Aug 26, 2020

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés